Comparison of the actions of 11.9 epoxymethano PGH2 and 9.11 AZO PGH2 on rat aorta and stomach strip preparations

Two synthetic thromboxane A₂ agonists were compared on two isolated smooth muslce preparations, the rat aorta and stomach-strip using a superfusion cascade. 11.9 epoxymethano-PGH₂ contracted both preparations in a concentration dependent manner. Cumulative concentration-response curves showed that azo PGH₂ was twice as active as 11.9 epoxymethano PGH₂ on the aorta and nearly four times as active as 11.9 epoxymethano PGH₂ on the stomach-strip. Statistical analysis of the agonist concentration-response curves showed a significant differences when responses to azo PGH₂ were compared on the two preparations and when responses to azo PGH₂ and 11.9 epoxymethano PGH₂ were compared to the aorta preparation. When EP045, a thromboxane receptor antagonist was used the PA₂ values obtained were not significantly different using the two agonists on the two preparations. The pA₂ values indicate that both agonists act on the same receptor but the comparison of the concentration-response curves suggest that azo PGH₂ may be acting at another receptor as well as the thromboxane receptor in the stomach-strip.     

Differential response of articular chondrocyte populations to thromboxane B2 and analogs of prostaglandin cyclic endoperoxides

The effects of two unsaturated fatty acids, prostaglandin E₂, thromboxane B₂ (TxB₂) and 2 analogs of PG endoperoxide on monolayer cultures of rabbit articular chondrocytes have been studied. Arachidonic and linoleic acids had no effect on either DNA or sulfated-glycosaminoglycan biosynthesis, while 13,14 dihydro-PGE₂ and PGE₂ markedly inhibited the former. Two epoxymethano analogs of endoperoxide PGH₂ (Em-PGH₂) at concentrations of 2.5 and 25 μg/ml stimulated cell proliferation while reducing ³⁵SO₄ incorporation. By contrast, Em-PGH₂ at lower concentrations (0.25 – 250 ng/ml) inhibited DNA synthesis in a dose-dependent manner. TxB₂ at 2.5 μg/ml did not alter cellular proliferation. At lower concentrations, 2.5 and 25 ng/ml, TxB₂ significantly stimulated sulfated-glycosaminoglycan biosynthesis in at least one of the chondrocyte populations tested. The results also demonstrated marked differences in the effects of TxB₂ and the Em-PGH₂ analogs on the partitioning of newly synthesized sulfated-proteoglycan between the cells and medium of these cell cultures.     

Biological activities of prostaglandin H1 analogs

The influences of epoxymethano and epoxycarbonyl analogs of PGH₁ on washed rabbit platelets, isolated smooth muscles and perfused heart preparations were investigated. On washed rabbit platelets, 11,9-epoxy-methano and 11,9-epoxycarbonyl PGH₁ produced a platelet aggregation whereas 9,11-epoxymethano and 9,11-epoxy-carbonyl PGH₁ produced an inhibition of arachidonic acid-induced platelet aggregation. On isolated rabbit thoracic aorta strips, 9,11-epoxycarbonyl PGH₁ showed strong contracting activity (5 times as active as 11,9-epoxy-methano PGH₂ and 31 times as active as PGH₂). All the analogs of PGH₁ caused contraction of guinea pig tracheal muscle and caused an increase of perfusion pressure in guinea pig heart, though 11,9-epoxymethano and epoxy-carbonyl PGH₁ were far more active than 9,11-epoxymethano and epoxycarbonyl PGH₁. Differences in biological activities between 11,9-epoxymethano and epoxycarbonyl PGH₁, and 9,11-epoxymethano and epoxycarbonyl PGH₁ indicate that the orientation of functional groups at C₉ and C₁₁ influences biological activities.     

Enrichment of platelet phospholipids with eicosapentaenoic acid and docosahexaenoic acid inhibits thromboxane A2/prostaglandin H2 receptor binding and function

Human platelet lipids were enriched in vitro with different amounts of either docosahexaenoic acid (22:6n-3), eicosapentaenoic acid (20:5n-3) or linoleic acid (18:2n-6). Of the total fatty acid incorporated, between 82 and 95% was associated with the phospholipid (PL) fraction, with the remainder as either neutral lipid or hydroxy fatty acid. Within the PL fraction, the majority (64% of total) of each fatty acid was incorporated into phosphatidylcholine. It was found that platelet aggregation induced by the thromboxane A2/prostaglandin H2 mimetic (15S)-hydroxy-11,9-(epoxymethano)prosta-5Z,13E-dienoic acid (U46619) was inhibited after PL enrichment with 22:6n-3 or 20:5n-3, but not after 18:2n-6 enrichment. The specificity of 22:6n-3 and 20:5n-3 for U46619 activation was demonstrated by the finding that neither fatty acid significantly inhibited thromboxane A2/prostaglandin H2-independent aggregation induced by A23187 or thrombin. Furthermore, enrichment with 22:6n-3 or 20:5n-3 resulted in inhibition of [3H]U46619 specific binding, while enrichment with 18:2n-6 did not affect binding. Scatchard analysis revealed that thromboxane A2/prostaglandin H2 receptor affinity for [3H]U46619 decreased 4.8-fold following 22:6n-3 incorporation. These results demonstrate that platelet phospholipid enrichment with 22:6n-3 or 20:5n-3 results in a selective inhibition of thromboxane A2/prostaglandin H2 receptor function.     

Biosynthesis of thromboxanes in human platelets. I. Characterization and assay of thromboxane systhetase

An enzyme system which catalyzes the rapid conversion of prostaglandin endoperoxide to thromboxane B₂ was found in the microsomal fraction of human platelet homogenate. The products of the reaction were identified by gas chromatography-mass spectrometry as thromboxane B₂ and the C-17 hydroxy fatty acid HHT. A simple radiometric TLC method was developed for the determination of the enzyme activity. Various parameters affecting the enzyme activity have been defined. Thromboxane synthetase was strongly inhibited by its substrate analogs. The activity was completely abolished when low amounts (5 × 10^?5$\text{M}$) of the 9,11 (epoxymethano) prostanoic acid was included in the assay mixture. The enzyme reaction was not affected by nonsteroidal antiinflammatory agents.     

Dietary linoleic acid affects phospholipid fatty acid composition in heart and eicosanoid production by cardiomyocytes from atlantic salmon (Salmo salar)

• 1.1. Atlantic salmon post-smolts were fed practical-type diets containing linoleic acid at 10, 25 or 45% of total dietary fatty acids for a period of 20 weeks.
• 2.2. As dietary linoleic acid was increased, individual phospholipids of heart contained increased levels of 18:2n-6, 20:2n-6, 20:3n-6 and 20:4n-6 and reduced levels of 20:5n-3. The ratio of n-3/n-6 polyunsaturated fatty acids in heart phospholipids decreased and the ratio of 20:4n-6/20:5n-3 increased.
• 3.3. An increased production of thromboxane B₂ occurred in isolated cardiac myocytes from fish given the highest dietary linoleic acid but the production of 6-keto prostaglandin F_1α was not significantly affected, nor was the activity of heart sarcoplasmic reticulum Ca²⁺-Mg²⁺ ATPase (EC 3.6.1.4).

     

Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: Pharmacological basis for a therapeutic approach

Addition of the one-, two- or three- series endoperoxide to human platelet-rich plasma tend to supress aggregation, through the action of their respective non-enzymatic breakdown products PGE₁, PGD₂, or PGD₃ all of which elevate cyclic AMP levels. On the other hand, these stable primary products do not arise in appreciable amounts from intrinsic endoperoxides generated from either endogenous or exogenous free fatty acids. 5,8,11,14,17-Eicosapentaenoic acid (EPA) suppresses arachidonic acid (5,8,11,14-eicosatetraenoic acid) conversion by cycloogygenase (as well as lipoxygenase) to aggregatory metabolites in platelets. Exogenously added EPA was capable of inhibiting PRP aggregation induced either by exogenous or endogenous (released by ADP or collagen) arachidonate. The hypothetical combination of an EPA-rich diet and a thromboxane synthetase inhibitor might abolish production of the pro-aggregatory species, thromboxane A₂, and enhance formation of the anti-aggregatory metabolite, prostacyclin.Whereas EPA is not detectably metabolized by platelets, dihomo-γ-linolenic acid (8,11,14,-eicosatrienoic acid) is primariley converted by cyclooxygenase and thromboxane synthetase into the inactive metabolite, 12-hydroxyheptadecadienoic (HHD) acid. Pretreatment of human platelet suspensions with the thromboxane synthetase inhibitor imidazole unmasks the aggregatory property of PGH₁ and DLL which was partially compromised by the PGE₁ formed. The combination of the thromboxane synthetase inhibitor and an adenylate cyclase inhibitor unmasks a complete irreversible aggregation by DLL or PGH₁. The basis of a dietary strategy that replaces AA with DLL must rely on the production by the platelet of an inactive metabolite (HHD) rather than thromboxane A₂.     

Effect of the thromboxane receptor antagonist EP 092 on endotoxin shock in the sheep

The thromboxane receptor antagonist EP 092 inhibits the acute pulmonary vascular response to endotoxin in the anaesthetized, closed-chest sheep. The increase in the TXB₂ level in arterial blood was not suppressed by EP 092. Intravenous infusion of the thromboxane mimetic 11,9-epoxymethano PGH₂, but not PGF_2α, raises pulmonary artery pressure and lowers arterial pO₂ similar to the endotoxin. Isolated strips of lobar pulmonary veins but not lobar arteries are contracted by low concentrations of 11,9-epoxymethano PGH₂ - the effects are potently inhibited by EP 092.     

Inhibition of platelet thromboxane synthetase by L-1-tosylamido-2-phenylethyl chloromethyl ketone

L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK) was found to inhibit several aspects of arachidonic acid (20:4) metabolism in human platelets; the primary effect being inhibition of thromboxane synthetase. Thromboxane B₂ (TxB₂) formation from exogenous 20:4 or PGH₂, or from endogenous 20:4, was inhibited by TPCK at concentrations between 0.1 and 0.5 mM. Formation of malondialdehyde (MDA) and 12-L-hydroxy-5,8,10-heptadecatrienoic acid (HHT), products which also arise from PGH₂, was inhibited to a similar extent. Inhibition of formation from 20:4 of 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid (HETE), the product of the lipoxygenase pathway, was observed; although the extent of this inhibition was less than that of TxB₂ formation. A small inhibitory effect of TPCK on the release of 20:4 from platelet phospholipids was also observed. This evidence indicated that while a number of reactions are inhibited by TPCK, the primary effect appears to be inhibition of thromboxane synthetase.     

A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.

The thromboxane synthetase inhibitor, 9,11-azoprosta-5,13-dienoic acid, blocks both platelet aggregation and the cyclic AMP lowering activity of the prostaglandin endoperoxide PGH₂. These data indicate PGH₂ must be converted into thromboxane A₂ in order to lower cAMP or induce platelet aggregation.     

Prostaglandins and myogenic control of tension in lower esophageal sphincter in vitro

Active tension is produced by the lower esophageal sphincter (LES) of North American opossum $\text{in vitro}$ by a myogenic mechanism. Strips of LES, but not those from the esophageal body, contracted to prostaglandin (PG)F_2α, stable expoxymethano derivatives of PGH₂ and to thromboxane B₂. Stable endoperoxides were more than 500 times more potent than PGF_2α. PGI₂ and 6-keto PGF_1α were weak relaxants of LES strips. LES strips transformed arachidonic acid into contractile substances. This transformation was prevented by agents which interfere with PG synthesis by inhibiting cyclo-oxygenase [indomethacin (IDM), 5,8,11,14-eicosatetraynoic acid (ETA) or thromboxane synthetase [imidazole]. Tranylcypromine 500 μg/ml also inhibited contractions to arachidonic acid. These agents also reduced muscle tone, so that endogenous PG formation may contribute to active tension in the LES. ETA and IDM increased tone before inhibiting it, and this effect was prevented by prior treatment with ETA or imidazole. There may also be an endogenous PG which inhibits LES tone. The possibility that this may be PGI₂ is discussed.     

Effects of all CIS-5, 8,11,14,17 eicosapentaenoic acid and PGH3 on platelet aggregation

In human platelet-rich plasma (PRP) eicosapentaenoic acid (EPA) inhibited platelet aggregation induced by a stable analogue of PGH₂ (U46619), arachidonic acid, collagen or ADP. EPA was more potent than oleic, linoleic, α-linolenic or γ-linolenic acids. In aspirin-treated platelets, aggregation induced by U46619 was inhibited to a similar extent by arachidonic acid or by EPA over a range of concentrations of 0.05–0.3 mM. EPA incubated with PRP did not induce the generation of a thromboxane (TXA)-like activity; indeed it prevented the formation of TXA₂ induced by arachidonic acid or by collagen. The anti-aggregatory activity of EPA was not influenced by inhibitors of cyclo-oxygenase and lipoxygenase. The anti-aggregatory action of EPA may be caused by a rapid occupancy by EPA of TXA₂/PGH₂ “receptors” on platelet membrane as well as by a slower displacement of arachidonic acid from platelet phospholipids by chemically unchanged molecules of EPA.Not all samples of PRP were irreversibly aggregated by PGH₂, but in those that were, PGH₃ also induced an immediate dose-dependent but reversible aggregation. After a 4 min incubation of non-aggregating doses of PGH₂ or PGH₃ (100–300 nM) with PRP a stable anti-aggregatory compound was detected. The inhibitory activity produced from PGH₃ was apparently more potent (ca 10 times) than that obtained from PGH₂. The anti-aggregating compounds were identified by TLC and GLC-MS as PGD₂ and PGD₃. The apparent difference of potency between PGD₂ and PGD₃ was attributed to the concurrent production of PGE₂ and PGE₃. PGE₂ prevented the inhibitory effect of PGD₂ whereas PGE₃ did not affect the activity of PGD₃.It is concluded that one of the reasons for the low incidence of myocardial infarction in Eskimos could be that the pro-aggregatory arachidonic acid is replaced in their phospholipids by the anti-aggregatory EPA.     

An alternate pathway to long-chain polyunsaturates: the FADS2 gene product ��8-desaturates 20:2n-6 and 20:3n-3

The mammalian Δ6-desaturase coded by fatty acid desaturase 2 (FADS2; HSA11q12-q13.1) catalyzes the first and rate-limiting step for the biosynthesis of long-chain polyunsaturated fatty acids. FADS2 is known to act on at least five substrates, and we hypothesized that the FADS2 gene product would have Δ8-desaturase activity. Saccharomyces cerevisiae transformed with a FADS2 construct from baboon neonate liver cDNA gained the function to desaturate 11,14-eicosadienoic acid (20:2n-6) and 11,14,17-eicosatrienoic acid (20:3n-3) to yield 20:3n-6 and 20:4n-3, respectively. Competition experiments indicate that Δ8-desaturation favors activity toward 20:3n-3 over 20:2n-6 by 3-fold. Similar experiments show that Δ6-desaturase activity is favored over Δ8-desaturase activity by 7-fold and 23-fold for n-6 (18:2n-6 vs 20:2n-6) and n-3 (18:3n-3 vs 20:3n-3), respectively. In mammals, 20:3n-6 is the immediate precursor of prostaglandin E1 and thromboxane B1. 20:3n-6 and 20:4n-3 are also immediate precursors of long-chain polyunsaturated fatty acids arachidonic acid and eicosapentaenoic acid, respectively. These findings provide unequivocal molecular evidence for a novel alternative biosynthetic route to long-chain polyunsaturated fatty acids in mammals from substrates previously considered to be dead-end products.     

Thromboxane induced red blood cell lysis

The two thromboxane A₂ mimetics, carbocyclic thromboxane A₂ (CTA₂) and U-46619 (9,11-methanoepoxy PGH₂) at concentrations of 400 ng/ml significantly enhanced the release of hemoglobin from both feline and human erythrocyte suspensions. This effect was significantly attenuated by the thromboxane receptor antagonist BM-13,505 indicating that the membrane leakiness is in some way receptor mediated. The effects also appear to be concentration-dependent over the range of 100–400 ng/ml. The membrane labilizing effect of thromboxane analogs is not due to a non-specific eicosanoid effect since iloprost, the stable prostacyclin analog, actually stabilized erythrocyte membranes. Moreover, synthetic thromboxane A₂ exerted similar effects to that of the two TxA₂-mimetics. This membrane labilizing action of thromboxanes may be important in propagating the other pathophysiologic effects of thromboxane A₂ in cardiovascular disease states.     

Some biological effects of prostaglandin endoperoxide analogs.

The effects of two methano-epoxy analogs of the prostaglandin endoperoxides PGG₂ and PGH₂ were tested on human platelets and rabbit aorta strips. One of these analogs, 9α, 11α-methano-epoxy-15- hydroxy-prosta-5, 13-dienoic acid, was 3.7 times more potent than the endoperoxide, PGG₂, as aggregating agent and was 6.2 times more active than PGH₂ in eliciting contractions of the isolated rabbit aorta. The analog initiated the platelet release reaction, but was less active than the endoperoxide in this respect. Furthermore, the release of ¹⁴C-serotonin induced by this analog was inhibited by indomethacin, which indicated that generation of endoperoxide was required.The corresponding 9α, 11α, epoxy-methano-analog was less active than the 9α, 11α, methano-epoxy analog in the test systems employed.     

Flg22‐triggered oxylipin production in Pyropia haitanensis

This study provides evidence that flg22, the most conserved 22‐amino acid peptide in the N‐terminal part of bacterial flagellin can trigger the defense responses of Pyropia haitanensis (Bangiales, Rhodophyta). The defense responses are a chain of events including release of H₂O₂ and free unsaturated fatty acids C20:4, consumption of C18:3, and the chemical or enzymatic oxidation of both C20 and C18 polyunsaturated fatty acids. Oxidized C20 and C18 fatty acids lead to the production of corresponding hydroperoxy and hydroxylated derivatives, such as 9‐hydroperoxy octadecadienoic acid, 8‐hydroperoxy eicosapentaenoic acid, and 8‐hydroxyl eicosapentaenoic acid, which could be further oxidatively metabolized to yield saturated aldehydes and ketone. Changes of three typical hormones jasmonate, methyl jasmonate, and salicylic acid were observed. Contrary to the increase of jasmonate and methyl jasmonate, salicylic acid was decreased. The expression of key enzymes of oxylipin pathway PhLOX and PhLOX2 were upregulated. However, some defense and antioxidant related genes including PhHsp 70, Phsod , and PhRboh were downregulated markedly at the early stage of flg22 challenge. Overall, our results imply that red algae have evolved a similar defense response and may share the conservative‐recognizing receptor for flg22 as in higher plants.     

Influence of short term dietary supplementation of different lipids on aggregation and arachidonic acid metabolism in rabbit platelets

Semisynthetic diets containing 8% by weight of either corn oil or butter were fed to male New Zealand rabbits for three weeks. The plasma cholesterol values were determined, the threshold concentrations for aggregation of platelet rich plasmas were measured for collagen and Na arachidonate, and the conversion of ¹⁴C arachidonic acid to thromboxane B₂ and hydroxy fatty acids (HETE and HHT) at 10, 20 and 40 μM substrate concentrations were studied. The thresholds for arachidonate induced aggregation were lower and the amplitudes of collagen induced aggregations were greater in the butter fed than in the corn oil fed rabbits. Conversions of arachidonic acid to thromboxane B₂ but not to hydroxy fatty acids were greater in the butter fed rabbits at 10 and 20 μM substrate. The observed changes were accompanied by only slight modifications of plasma cholesterol levels.     

Metabolism and effect of prostaglandin H2 in adipose tissue

Prostaglandin H₂ (PGH₂) inhibited noradrenaline induced cyclic AMP accumulation in isolated rat fat cells in a dose-dependent manner. IC₅₀ was 10 – 25 ng/ml both in the absence and in the presence of theophylline. The degree of inhibition produced by PGH₂ increased with time of incubation. A stable PGH₂ analog did not inhibit cyclic AMP accumulation. PGH₂ was rapidly converted by isolated fat cells to PGD₂, PGE₂ and PGH_2α, but no formation of thromboxane B₂ was found either or . PGE₂ was a more potent inhibitor than PGH₂ of noradrenaline induced cyclic AMP accumulation. PGD₂ enhanced cyclic AMP accumulation in a limited concentration interval, while PGF_2α was essentially uneffective.Our results suggest that PGH₂ is an inhibitor of cyclic AMP formation in isolated rat fat cells only after conversion to PGE₂. A physiological role for PGH₂ as a modulator of lipolysis is considered unlikely.     

Prostaglandin endoperoxides IV. Effects on smooth muscle

The effect on smooth muscle of the endoperoxides PGG₂ and PGH₂, which are intermediates in prostaglandin biosynthesis, was studied in different systems $\text{in vitro}$ and $\text{in vivo}$. On gastrointestinal smooth muscle (gerbil colon, rat stomach) PGG₂ and PGH₂ produced contractions comparable to those of PGE₂ and PGF_2a whereas contractions elicited on vascular (rabbit aorta) and airway (guinea-pig trachea) smooth muscle were considerably greater than those of PGE₂ and PGF_2a respectively. On intravenous injection into guinea-pigs PGG₂ and PGH₂ caused a triphasic change in blood pressure and were 8–10 times more effective than PGF_2a in producing an increase in tracheal insufflation pressure. When given as aerosols the unstable endoperoxides were less effective than PGF_2a. It is concluded that the endoperoxides are potent smooth muscle stimulants and that they are more effective than their degradation products (PGD₂, PGE₂, PGF_2a) in some systems.     

Inhibition of PGE1-stimulated cAMP accumulation in human platelets by thromboxane A2

The prostaglandin endoperoxide PGH₂, HHT, HETE, thromboxane A₂, and thromboxane B₂, which are all products of arachidonic acid metabolites of human platelets, were tested for their ability to modulate platelet cyclic nucleotide levels. None of the compounds tested altered the basal level of cAMP or cGMP, and only PGH₂ and thromboxane A₂ inhibited PGE₁-stimulated cAMP accumulation. Thromboxane A₂ was found to be a more potent inhibitor of PGE₁-stimulated cAMP accumulation and inducer of platelet aggregation thatn PHG₂.